2024
Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US
Kerekes D, Frey A, Prsic E, Tran T, Clune J, Sznol M, Kluger H, Forman H, Becher R, Olino K, Khan S. Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US. JAMA Oncology 2024, 10: 342-351. PMID: 38175659, PMCID: PMC10767643, DOI: 10.1001/jamaoncol.2023.6025.Peer-Reviewed Original ResearchNon-small cell lung cancerEnd of lifeMonth of deathImmunotherapy initiationCohort studyMAIN OUTCOMEStage IV non-small cell lung cancerCharlson-Deyo comorbidity indexHigh metastatic burdenInitiation of immunotherapyNational prescribing patternsRisk-adjusted patientsImmune checkpoint inhibitorsRetrospective cohort studyStage IV melanomaPercentage of patientsHigh-volume centersLocation of metastasesLow-volume centersOdds of deathCell lung cancerNational Clinical DatabaseLow-volume facilitiesDrug Administration approvalCheckpoint inhibitors
2020
Effect of concurrent beta-blocker use in patients receiving immune checkpoint inhibitors for advanced solid tumors.
Patel V, Qin Q, Wang B, Gogerly-Moragoda M, Mellgard G, Zhong X, Parikh A, Leiter A, Gallagher E, Oh W, Galsky M, Tsao C. Effect of concurrent beta-blocker use in patients receiving immune checkpoint inhibitors for advanced solid tumors. Journal Of Clinical Oncology 2020, 38: e15068-e15068. DOI: 10.1200/jco.2020.38.15_suppl.e15068.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsDisease control rateClinical activity of immune checkpoint inhibitorsActivity of immune checkpoint inhibitorsAdvanced solid tumorsBeta blockersSolid tumorsCheckpoint inhibitorsDose of immune checkpoint inhibitorsCD8+ T cell activationClinical activityImproved disease control rateClinical outcomes of patientsAntitumor immune activityPharmacological beta-blockadeRadiographic complete responseEffects of beta blockersECOG performance statusLocation of metastasesOutcomes of patientsBeta-blocker useT cell activationInhibited tumor growthMultivariate logistic regression modelStable diseaseCharacterizing patterns of disease progression in patients with genitourinary cancers treated with immune checkpoint inhibitors.
Patel V, Qin Q, Mellgard G, Parikh A, Wang B, Alerasool P, Garcia P, Jaladanki S, Leiter A, Carroll E, Brooks D, Shimol J, Eisenberg E, Gallagher E, Galsky M, Oh W, Tsao C. Characterizing patterns of disease progression in patients with genitourinary cancers treated with immune checkpoint inhibitors. Journal Of Clinical Oncology 2020, 38: 482-482. DOI: 10.1200/jco.2020.38.6_suppl.482.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsPatterns of disease progressionRenal cell carcinomaUrothelial carcinomaCheckpoint inhibitorsCancer treated with immune checkpoint inhibitorsTreated with immune checkpoint inhibitorsDisease progressionImmune checkpoint inhibitor doseSites of disease involvementAdvanced urothelial carcinomaLocation of metastasesSite of diseaseFisher's exact testReduced rates of hospitalizationLoss of appetiteRates of hospitalizationCell carcinomaDisease involvementClinical factorsExact testQuality-of-lifeMedical historyPatientsHospitalization details
2006
Multivariate analysis identifies factors that affect survival after stereotactic radiosurgery for brain metastases
Diluna M, King J, Knisely J, Bond J, De Lotbiniere A, Chiang V. Multivariate analysis identifies factors that affect survival after stereotactic radiosurgery for brain metastases. Journal Of Clinical Oncology 2006, 24: 11500-11500. DOI: 10.1200/jco.2006.24.18_suppl.11500.Peer-Reviewed Original ResearchCell lung carcinomaStereotactic radiosurgeryBrain metastasesCerebral metastasesSurgical resectionEsophageal cancerLung carcinomaBreast cancerNon-small cell lung carcinomaSmall cell lung carcinomaSystemic controlConnecticut Tumor RegistryLocation of metastasesNumber of metastasesPatient-related factorsTotal tumor burdenSystemic disease controlKaplan-Meier plotsSignificant independent predictorsSurvival dataTotal tumor volumeMedian survivalWorse survivalImproved survivalIndependent predictors
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply